RAPT Therapeutics has called it quits on a clinical programme evaluating zelnecirnon (RPT193) in inflammatory disorders ...

The primary reason for the Hold rating is the company’s decision to terminate the development of zelnecirnon following feedback from the FDA. This decision was influenced by the clinical hold placed ...

Shares of RAPT Therapeutics (NASDAQ:RAPT) plunged 46% in early trading Monday after the company said it was scrapping ...

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.

RAPT Therapeutics has ended its zelnecirnon program following safety concerns raised by the FDA after a severe adverse event ...

As previously reported, JPMorgan analyst Anupam Rama downgraded Rapt Therapeutics (RAPT) to Underweight from Neutral after the company announced the discontinuation of the zelnecirnon program in ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

Shares of RAPT Therapeutics touched an all-time low following news the company terminated its zelnecirnon program after feedback from the Food and Drug Administration. In the last hour of Monday's ...

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...